TABLE 3

Time to culture negativity and percentage of patients with conversion of sputum culture to negative by 8 weeks of therapy, by characteristica

CharacteristicMedian TTN (days [95% CI])HR (95% CI)P value for HRNo. (%) of patients with culture conversion at 8 wkP value for culture conversion
DM
    Yes39 (30, 43)1.08 (0.82, 1.41)0.5973 (83.91)0.79
    No39 (28, 42)99 (82.50)
HbA1c value (%)
    <5.639 (28, 42)1.07 (0.92, 1.26)0.3778 (83.87)0.59
    5.6–6.539 (28, 42)0.92 (0.66, 1.28)0.6145 (78.95)
    >6.537 (28, 43)1.18 (0.86, 1.62)0.3149 (85.96)
Age (yr)
    <5039 (30, 42)0.85 (0.62, 1.17)0.32138 (83.13)0.92
    >5040 (28, 56)33 (82.50)
Sex
    Male41 (37, 44)1.54 (1.15, 2.07)0.004106 (79.10)0.04
    Female28 (27, 39)65 (90.28)
Bacterial burden
    High42 (39, 85)1.40 (1.18, 1.66)<0.00117 (73.9)0.01
    Medium42 (39, 53)67 (75.28)
    Low31 (28, 42)58 (92.06)
    Very low26 (16, 34)26 (92.86)
Cavity
    No42 (34, 52)0.88 (0.64 1.19)0.4282 (81.19)
    Yes44 (39, 54)81 (84.38)
Rifampin Cmax
    Below target39 (31, 42)1.10 (0.74 1.64)0.65133 (82.6)0.77
    Above target40 (27, 43)38 (84.44)
Isoniazid Cmax
    Below target43 (28, 57)1.10 (0.79 1.52)0.5821 (80.77)0.74
    Above target39 (30, 42)151 (83.43)
Pyrazinamide Cmax
    Below target37 (28, 40)0.72 (0.54 0.95)0.0280 (89.89)0.02
    Above target41 (30, 42)81 (77.14)
  • a TTN, time to culture negativity; HR, hazard ratio.